Tobacco Harm Reduction
Expert Bioanalytical Services for Regulated Biomarker Studies
Nicotine Pharmacokinetic Analysis for Regulatory Submissions
Trusted Bioanalytical Services Tailored to Your Specific Application
Integrated Solutions for Seamless Sample Management World Wide
Do you have any questions about our services?
We would be happy to advise and support you with your project or your study. Send us your request and tell us your specific wishes.
Our biomarker methods
| Biomarker | Exposure to | Matrix | Analytical Technique | Reference |
|---|---|---|---|---|
| 1-Aminonaphthalene (1-AN) | 1-Aminonaphthalene | Urine | GC-MS | |
| 1-Hydroxyphenanthrene (1-OH-Phe) | Phenanthrene | Urine | LC-MS/MS | |
| 1-Hydroxypyrene (1-OH-Pyr) | Pyrene | Urine | LC-MS/MS | |
| 1-Naphthol (1-Hydroxynaphthalene, 1-OH-Nap) | Naphthalene | Urine | LC-MS/MS | |
| 1,3-Butadiene | Tobacco Smoke | ETS | GC-MS | |
| 11-dehydro-TXB2 | Inflammation | Urine | LC-MS/MS | |
| 12(S)-HETE | Inflammation | Urine | LC-MS/MS | |
| 2-(Carboxyl-1-methylethyl)mercapturic acid (CMEMA) | Crotonaldehyde | Urine | LC-MS/MS | |
| 2-Aminonaphthalene (2-AN) | 2-Aminonaphthalene | Urine, ETS | GC-MS | |
| 2-Hydroxy-1-phenylethylmercapturic acid (PHEMA 1) | Styrene | Urine | LC-MS/MS |
Assessment of the Exposure to Tobacco-Specific Nitrosamines and Minor Tobacco Alkaloids in Users of Various Tobacco/Nicotine Products
Scherer G, Scherer M, Mütze J, Hauke T, Pluym N
Chemical Research in Toxicology, doi: 10.1021/acs.chemrestox.2c00020
Wastewater-Based Epidemiology (WBE): Potential Application for Assessing the Use of Conventional and New Generation Tobacco and Nicotine Products
Gerhard Scherer, Nikola Pluym, Max Scherer
Contributions to Tobacco & Nicotine Research
Assessing the exposure to ‘smoke’ from electronic cigarettes by biomarkers
Scherer G, Hagedorn H-W, Riedel K, Scherer M
CORESTA SSPT 2013, Seville, Spain
Biomarkers of Exposure Specific to E-vapor Products Based on Stable-Isotope Labeled Ingredients
Landmesser A, Scherer M, Pluym N, Sarkar M, Edmiston J, Niessner R, Scherer G
Nicotine & Tobacco Research, Volume 21, doi: 10.1093/ntr/nty204
Biomarkers of exposure specific to e-vapor products based on stable-isotope labeled ingredients
Landmesser A, Scherer M, Scherer G, Sarkar M, Edmiston J, Pluym N
SRNT 2018, Baltimore, USA
Biomarkers of exposure specific to e-vapor products based on stable-isotope labelled ingredients – methods
Landmesser A, Pluym N, Scherer G, Sarkar M, Edmiston J, Scherer M
CORESTA SSPT 2017, Kitzbühel, Austria
Biomarkers of exposure specific to e-vapor products based on stable-isotope labelled ingredients–results
Landmesser A, Scherer M, Scherer G, Sarkar M, Edmiston J, Pluym N
CORESTA SSPT 2017, Kitzbühel, Austria
Biomarkers of exposure specific to e-vapor products based on stable-isotope labelled ingredients–study design
Landmesser A, Pluym N, Scherer G, Sarkar M, Edmiston J, Scherer M
CORESTA SSPT 2017, Kitzbühel, Austria
Collaborative Method Performance Study of the Measurement of Nicotine, Its Metabolites, and Total Nicotine Equivalents in Human Urine
Wang L, Bernert JT, Benowitz NL, Feng J, Jacob P 3rd, McGahee E, Caudill SP, Scherer G, Scherer M, Pluym N, Doig MV, Newland K, Murphy SE, Caron NJ, Sander LC, Shimizu M, Yamazaki H, Kim S, Langman LJ, Pritchett JS, Sniegoski LT, Li Y, Blount BC, Pirkle JL
Cancer Epidemiology, Biomarkers & Prevention, Volume 27, doi: 10.1158/1055-9965
Saliva as a matrix for human biomonitoring in occupational and environmental medicine
Michalke B, Rossbach B, Göen T, Schäferhenrich A, Scherer G
International Archives of Occupational and Environmental Health, volume 88, doi: 10.1007/s00420-014-0938-5
Simple, fast and sensitive LC-MS/MS analysis for the simultaneous quantification of nicotine and 10 of its major metabolites
Piller M, Gilch G, Scherer G, Scherer M
Journal of Chromatography B, Volumes 951–952, doi: 10.1016/j.jchromb.2014.01.025
Ultra-sensitive method for the determination of nicotine in PK studies with next generation products
Wanderer F, Pluym N, Scherer G, Scherer M
CORESTA Congress 2016, Berlin, Germany
Assessment of nicotine delivery and uptake in users of various tobacco / nicotine products
Scherer G, Mütze J, Pluym N, Scherer M
Current Research in Toxicology, Volume 3, 100067
A simple and robust UPLC-SRM/MS method to quantify urinary eicosanoids
Sterz K, Scherer G, Ecker J
Journal of Lipid Research, Volume 53, doi: 10.1194/jlr.D023739
Analysis of Urinary Eicosanoids by LC-MS/MS Reveals Alterations in the Metabolic Profile after Smoking Cessation
Goettel M, Niessner R, Scherer M, Scherer G, Pluym N
Chemical Research in Toxicology, Volume 31, doi: 10.1021/acs.chemrestox
Identifying suitable biomarkers of biological effects (BOBEs) for evaluating reduced risk products
Scherer G, Pluym N, Scherer M
CORESTA Congress 2018, Biomarker Workshop, Kunming, China
Metabolomic Fingerprinting in Various Body Fluids of a Diet-Controlled Clinical Smoking Cessation Study Using a Validated GC-TOF-MS Metabolomics Platform
Goettel M, Niessner R, Mueller D, Scherer M, Scherer G, Pluym N
Journal of Proteome Research, Volume 16(10), doi: 10.1021/acs.jproteome.7b00128.
Review of biomarkers to assess the effects of switching from cigarettes to modified risk tobacco products
Peck MJ, Sanders EB, Scherer G, Luedicke F, Weitkunat R
Biomarkers, Volume 23(3), doi: 10.1080/1354750X.2017.1419284
Suitability of biomarkers of biological effects (BOBEs) for assessing the likelihood of reducing the tobacco related disease risk by new and innovative tobacco products: A literature review
Scherer G
Regulatory Toxicology and Pharmacology, Volume 94, doi: 10.1016/j.yrtph.2018.02.002
Determination of flavors and their metabolites in e-liquids and biological fluids - Identification of biomarkers of exposure to prominent e-cigarette flavors
Riedel K, Pluym N, Scherer G, Scherer M
CORESTA SSPT 2015, Jeju, South Korea
Time trend of exposure to secondhand tobacco smoke and polycyclic aromatic hydrocarbons between 1995 and 2019 in Germany – Showcases for successful European legislation
Therese Burkhardt, Max Scherer, Gerhard Scherer, Nikola Pluym, Till Weber, Marike Kolossa-Gehring
Environmental Research, doi: 10.1016/j.envres.2022.114638
Untargeted metabolomic profiling in saliva of smokers and nonsmokers by a validated GC-TOF-MS method
Mueller DC, Piller M, Niessner R, Scherer M, Scherer G
Journal of Proteome Research, Volume 13, doi: 10.1021/pr401099r
Urinary cotinine and exposure to passive smoke in children and adolescents in Germany – Human biomonitoring results of the German Environmental Survey 2014–2017 (GerES V)
Domenica Hahn, Maria Schmied-Tobies, Enrico Rucic, Nikola Pluym, Max Scherer, Malgorzata Debiak, Aline Murawski, Marike Kolossa-Gehring
Environmental Research doi.org/10.1016/j.envres.2022.114320
The impact of European legislation on the reduction of Environmental Tobacco Smoke and Polycyclic Aromatic Hydrocarbons between 1995 and 2019 in Germany
Therese Burkhardt, Max Scherer, Gerhard Scherer, Till Weber, Nikola Pluym, Marike Kolossa-Gehring
ISES 2022, Lisbon
Determination of tobacco-specific N-nitrosamines in urine of smokers and non-smokers
Kavvadias D, Scherer G, Cheung F, Errington G, Shepperd J, McEwan M
Biomarkers, Volume 14, doi: 10.3109/13547500903242883
Simultaneous determination of four tobacco-specific N-nitrosamines (TSNA) in human urine
Kavvadias D, Scherer G, Urban M, Cheung F, Errington G, Shepperd J, McEwan M
Journal of Chromatography B, Volume 877, doi: 10.1016/j.jchromb.2009.03.009
Assessment of the Exposure to NNN in the Plasma of Smokeless Tobacco Users
Pluym N, Scherer G, Edmiston J, Jin X, Sarkar M, Scherer M
Chemical Research in Toxicology, doi:10.1021/acs.chemrestox.1c00431
NNN a suitable biomarker of exposure from smoke and new nicotine delivery products?
Pluym N, Taucher J, Scherer G, Scherer M
CORESTA SSPT 2019, Hamburg, Germany
Quantitative analysis of NNN in plasma by LC-MS/MS: a suitable alternative to urinary determination to assess the exposure to this important toxicant
Pluym N, Sibul F, Jin X, Edmiston J, Sarkar M, Scherer G, Scherer M
CORESTA SSPT 2021, Virtual
Analysis of 18 Urinary Mercapturic Acids by two Multiplex-LC-MS/MS Methods
Pluym N, Gilch G, Scherer G, Scherer M
CORESTA Congress 2014, Quebec, Canada
Analysis of 18 urinary mercapturic acids by two high-throughput multiplex-LC-MS/MS methods
Pluym N, Gilch G, Scherer G, Scherer M
Analytical and Bioanalytical Chemistry, Volume 407, doi: 10.1007/s00216-015-8719-x
Benzene metabolite SPMA and acrylamide metabolites AAMA and GAMA in urine of children and adolescents in Germany - human biomonitoring results of the German Environmental Survey 2014-2017 (GerES V)
Schwedler G, Murawski A, Schmied-Tobies MIH, Rucic E, Scherer M, Pluym N, Scherer G, Bethke R, Kolossa-Gehring M
Environmental Research, Volume 192, doi: 10.1016/j.envres.2020.110295
Comparison of urinary mercapturic acid excretions in users of various tobacco/nicotine products
Gerhard Scherer, Nikola Pluym, Max Scherer
Drug Testing and Analysis DOI: 10.1002/dta.3372
A correlation study applied to biomarkers of internal and effective dose for acrylonitrile and 4-aminobiphenyl in smokers
Scherer G, Newland K, Papadopoulou E, Minet E
Biomarkers, Volume 19(4), doi: 10.3109/1354750X.2014.910271
Assessment of the potential vaping-related exposure to carbonyls and epoxides using stable isotope-labeled precursors in the e-liquid
Landmesser A, Scherer M, Scherer G, Sarkar M, Edmiston J, Niessner R, Pluym N
Archives of Toxicology, doi:10.1007/s00204-021-03097-x
Analytical methods for the determination of carbonyls in aerosol from e-vapor products and cigarette smoke and their urinary biomarkers of exposure
Landmesser A, Scherer M, Scherer G, Pluym N
CORESTA Congress 2018, Kunming, China
Analysis of aldehydes, propylene oxide and glycidol in tobacco smoke and e-cigarette vapor and their respective urinary biomarkers
Landmesser A, Scherer G, Pluym N, Scherer M
CORESTA SSPT 2019, Hamburg, Germany
Novel biomarkers to characterize exposure to aldehydes from e-vapor products based on stable-isotope constituents
Landmesser A, Scherer M, Scherer G, Sarkar M, Edmiston J, Pluym N
CORESTA Congress 2018, Kunming, China
Novel biomarkers to characterize the specific exposure to aldehydes or epoxides from e-vapor products based on stable-isotope labeled constituents
Landmesser A, Scherer M, Scherer G, Pluym N
SRNT 2019, San Francisco, USA
Urinary Mercapturic Acids and a Hemoglobin Adduct for the Dosimetry of Acrylamide Exposure in Smokers and Nonsmokers
Urban M, Kavvadias D, Riedel K, Scherer G, Tricker AR
Inhalation Toxicology, Volume 18, doi: 10.1080/08958370600748430
Assessment of the Exposure to Aromatic Amines in Users of Various Tobacco/Nicotine Products
Gerhard Scherer, Kirsten Riedel, Nikola Pluym, Max Scherer
ACS Omega, doi: 10.1021/acsomega.2c06130
Determination of three carcinogenic aromatic amines in urine of smokers and nonsmokers
Riedel K, Scherer G, Engl J, Hagedorn H-W, Tricker AR
Journal of Analytical Toxicology, Volume 30, doi: 10.1093/jat/30.3.187
External quality assurance schemes (EQUASs) and interlaboratory comparison investigations (ICIs) for the human biomonitoring of aromatic amines in urine as part of the quality assurance programme under HBM4EU
Stefanie Nübler, Therese Burkhardt, Moritz Schäfer, Johannes Müller, Karin Haji-Abbas-Zarrabi, Nikola Pluym, Max Scherer, Gerhard Scherer, Marta Esteban-Lopez, Argelia Castaño, Hans G. J. Mol, Holger M. Koch, Jean-Philippe Antignac, Jana Hajslova, Katrin Vorkamp, Thomas Göen
Analytical Methods
Propylene glycol as a specific biomarker for e-cigarette use Showcase of a novel Orbitrap-MS-based exposomics approach
Nikola Pluym, Therese Burkhardt, Alpesh Kachhadia, Gerhard Scherer, Max Scherer
ISES 2022, Lisbon
Propylene glycol: A Biomarker of Exposure specific to E-Cigarette Consumption
Burkhardt T, Pluym N, Scherer G, Scherer M
SRNT 2022, Baltimore (Hybrid), USA
1,2-Propylene Glycol: A Biomarker of Exposure Specific to e-Cigarette Consumption
Burkhardt T, Pluym N, Scherer G, Scherer M
Separations, 8, 180, doi: 10.3390/separations8100180
A liquid chromatography/tandem mass spectrometry (LC-MS/MS) method for the determination of phenolic polycyclic aromatic hydrocarbons (OH-PAH) in urine of non-smokers and smokers
Ramsauer B, Sterz K, Hagedorn H-W, Engl J, Scherer G, McEwan M, Errington G, Shepperd J, Cheung F
Analytical and Bioanalytical Chemistry, volume 399, doi:10.1007/s00216-010-4355-7
Assessment of the exposure to polycyclic aromatic hydrocarbons in users of various tobacco/nicotine products by suitable urinary biomarkers
Gerhard Scherer, Max Scherer, Nadine Rögner, Nikola Pluym
Archives of Toxicology doi.org/10.1007/s00204-022-03349-4
Polycyclic aromatic hydrocarbons (PAH) in urine of children and adolescents in Germany - human biomonitoring results of the German Environmental Survey 2014-2017 (GerES V)
Murawski A, Roth A, Schwedler G, Schmied-Tobies MIH, Rucic E, Pluym N, Scherer M, Scherer G, Conrad A, Kolossa-Gehring M
International Journal of Hygiene and Environmental Health, Volume 226, doi: 10.1016/j.ijheh.2020.113491
A Sensitive LC–MS/MS Method for the Quantification of 3-Hydroxybenzo[a]pyrene in Urine-Exposure Assessment in Smokers and Users of Potentially Reduced-Risk Products
Rögner N, Hagedorn H-W, Scherer G, Scherer M, Pluym N
Separations, 8(10), 171, doi: 10.3390/separations8100171
Analysis of 3-hydroxybenzo[a]pyrene in urine as a biomarker of exposure for benzo[a]pyrene in smokers and users of potentially reduced risk products
Rögner N, Scherer M, Scherer G, Pluym N
Global Forum on Nicotine 2021, Virtual
Analysis of 3-hydroxybenzo[a]pyrene in urine as a biomarker of exposure for benzo[a]pyrene in smokers and users of potentially reduced risk products
Scherer M, Rögner N, Scherer G, Pluym N
CORESTA SSPT 2021, Virtual
A sensitive GC–MS/MS method for the quantification of benzo[a]pyrene tetrol in urine
Max Scherer, Fabian Pilz, Antonia Gärtner, Gerhard Scherer, Nikola Pluym
CORESTA Congress 2024, Edinburgh, UK
A sensitive GC–MS/MS method for the quantification of benzo[a]pyrene tetrol in urine
Fabian Pilz, Antonia Gärtner, Nikola Pluym, Gerhard Scherer, Max Scherer
Analytical and Bioanalytical Chemistry
Pioneers in biomarker research
Almost all of the biomarker methods developed at ABF were published in peer-reviewed journals, a fact that supports the validity, transparency and scientific evidence of the bioanalysis especially of importance for regulatory submissions